# Study With Elranatamab Versus Lenalidomide in Patients With Newly Diagnosed Multiple Myeloma After Transplant

Source: https://onco.cc/trials/nct05317416/  
OnCo record `nct05317416` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of Elranatamab, Lenalidomide in multiple myeloma, run by Pfizer, active and no longer recruiting.

## Summary

Study With Elranatamab Versus Lenalidomide in Patients With Newly Diagnosed Multiple Myeloma After Transplant is a phase 3 interventional study registered as NCT05317416 by Pfizer, with 854 participants enrolled, started 2022-03-25 and due to reach its primary completion in 2027-08-04. Interventions recorded: Elranatamab, Lenalidomide, Lenalidomide, Elranatamab. Conditions listed: Multiple Myeloma. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT05317416
- Phase: 3
- Setting: A RANDOMIZED, 2-ARM, PHASE 3 STUDY OF ELRANATAMAB (PF-06863135) VERSUS LENALIDOMIDE IN PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA AFTER UNDERGOING AUTOLOGOUS STEM-CELL TRANSPLANTATION
- Sponsor: Pfizer
- Enrolled: 854

## Sources

- ClinicalTrials.gov NCT05317416: https://clinicaltrials.gov/study/NCT05317416

## Connected records

- cancers: [Multiple myeloma](https://onco.cc/cancers/multiple-myeloma/)
- drugs: [Elranatamab](https://onco.cc/drugs/elranatamab/), [Lenalidomide](https://onco.cc/drugs/lenalidomide/)
- companies: [Pfizer (incl. Seagen)](https://onco.cc/companies/pfizer/)

---
JSON: https://onco.cc/api/v1/entities/nct05317416.json